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OBJECTIVES We present a meta-analysis based on three recent, substantial, randomized outcome trials and
several smaller trials that compared calcium channel blockers (CCBs) with conventional
therapy (diuretics or beta-blockers) or with angiotensin-converting enzyme (ACE) inhibitors
BACKGROUND There is continuing uncertainty about the safety and efficacy of CCBs in the treatment of
hypertension. Previous meta-analyses conflict and suggest that CCBs increase myocardial
infarction (MI) or protect from stroke.
METHODS Standard procedures for meta-analysis were used to analyze three major trials on 21,611
patients and another three lesser studies to a total of 24,322 patients.
RESULTS Calcium channel blockers have a strikingly similar risk of total and cardiovascular mortality
and of major cardiovascular events to conventional therapy. Calcium channel blockers give a
lower risk of nonfatal stroke (25%, p  0.001) and a higher risk of total MI (18%, p 
0.013), chiefly nonfatal (18%). After performing the Bonferroni correction for multiplicity,
these p values become 0.004 and 0.052, respectively. When compared with ACE inhibitors
in 1,318 diabetic patients, CCBs had a substantially higher risk of nonfatal (relative risk
[RR]  2.259) and total MI (RR  2.204, confidence interval 1.501 to 3.238; p  0.001 or
0.004 with Bonferroni correction). Total and cardiovascular mortality rates are similar. To
confirm the hypothesis that ACE inhibitors are superior to CCBs in diabetic patients requires
more trial data, especially with renal end points.
CONCLUSIONS Mortality (total and cardiovascular) and major cardiovascular events with CCBs were
apparently similar to those events seen with conventional first-line therapy (diuretics or
beta-blockers). Stroke reduction more than balanced increased MI. In diabetics, CCBs may
be less safe than ACE inhibitors. (J Am Coll Cardiol 2002;39:315–22) © 2002 by the
American College of Cardiology
Considerable evidence points to the cardiovascular harm of
short-acting dihydropyridines, such as capsular nifedipine,
although several studies suggest that longer acting calcium
channel blockers (CCBs) may have fewer or possibly no
adverse effects (1,2). Nonetheless, the safety of longer acting
CCBs in the long-term treatment of hypertension has
remained an open issue. The recent reporting of three large,
well designed, randomized, controlled trials (3–5) requires a
fresh assessment of the safety and efficacy of CCBs in
hypertension. These and other studies have given rise to two
important recent meta-analyses (6,7). Furberg’s group (6)
concluded that CCBs as initial antihypertensive therapy
increased myocardial infarction (MI) by 26%, whereas the
Blood Pressure Trialists (7) concluded that there was a
significant decrease in stroke with CCBs, with only a
borderline increase in MI. Because both groups found that
CCBs and conventional therapy had indistinguishable ef-
fects on mortality (total and cardiovascular), we reasoned
that a consideration of nonfatal events might help explain
the discrepancies. We have separately compared CCB-
based therapy with “conventional therapy,” initially with
diuretics or beta-blockers and thereafter with angiotensin-
converting enzyme (ACE) inhibitors. There are two reasons
for the separate comparisons. First, an influential U.S.
document suggests that such conventional treatment should
be the first-line antihypertensive therapy, with ACE inhib-
itors selected only for specific subgroups (8). Thus, it is
crucial to know how CCBs compare with conventional
therapy. Second, ACE inhibitors may have cardioprotective
properties beyond blood pressure control (9,10). In contrast
to both the Blood Pressure Trialists (7) and Furberg group
(6), we also assessed diabetic patients separately from others,
in view of the well-known increase of cardiovascular risk in
diabetics. In addition, in contrast to both studies, we graded
the quality of the studies in our meta-analysis, and only the
three major studies received grade A (Table 1). We have
also considered three lesser trials to which we assigned a
grade B status (11–15) and one trial that we excluded (see
Methods). These comparisons point the way toward
evidence-based and outcome-related comparisons of the
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efficacy and safety of CCBs and other groups of antihyper-
tensive agents. Our results also allow explanation of the two
apparently conflicting meta-analyses by Furberg’s group (6)
and the Blood Pressure Trialists (7).
METHODS
The major part of the study concerns the comparison
between initial therapy with CCBs and conventional ther-
apy, where the latter is defined as initial therapy with either
a diuretic or beta-blocker, but not both. To gather all
eligible trials of hypertension, we conducted a continuous
search of the published data over five years (1,16), and we
cross-checked our trial inclusions with those of Furberg’s
group (6). Ideally, the trials had to satisfy six criteria
(translated into points): 1) randomization; 2) blinded fash-
ion or with the Prospective, Randomized, Open, Blinded
End point evaluation design, as in the Swedish Trial in Old
Patients with Hypertension-2 (STOP-Hypertension-2) (4)
and Nordic Diltiazem study (5); 3) clearly and prospectively
predefined clinical end points, such as mortality, stroke,
heart failure and MI; 4) inclusion of 1,000 patients, to
give reliable numbers of outcome measures; 5) use of
medium- or long-acting CCBs, but not with short-acting
CCBs, which are known to increase cardiovascular end
points; and 6) duration of 2 years. As pointed out by
Flather et al. (17), most of the clinically useful information
comes from the large randomized trials of 1,000 patients.
Six trials involving conventional therapy satisfied three or
more of these criteria. Trials that satisfied at least 5 of those
6 points were assigned a grade A status (Table 1). Grade B
trials satisfied only 4 points.
The sum of events due to MI, stroke and heart failure was
taken as major cardiovascular events, and the sum of deaths
caused by these events was the total cardiovascular mortality
(Tables 2 and 3).
As an example of the grading system, the National
Intervention Cooperative Study in Elderly Hypertensives
study (11) was graded as B because of the small number of
patients and because the clinical end points were not
predefined. The Verapamil in Hypertension Atherosclerosis
Study (12) was graded as B, because the cardiovascular end
points were a secondary aim and were not clearly predefined,
and the trial was largely open-label. The Multicenter
Isradipine Diuretic Atherosclerosis Study (MIDAS) (13)
received the lowest grade B rating, because it used a
short-acting dihydropyridine that is known to increase
cardiovascular risk (1,18). The primary end points did not
include clinical outcomes, nor were these predefined.
The Cardiovascular Study of the Elderly (CASTEL),
although included by Furberg’s group (6), was excluded
because of a fundamental trial defect: CASTEL compared
an inadequate dose of nifedipine retard tablets, which need
to be given twice a day, but were only given once a day with
dual therapy with two long-acting agents: high-dose ateno-
lol and a diuretic agent (19). Thus, comparable 24-h blood
pressure control in the two groups could not have been
achieved. Furthermore, CASTEL was seriously imbal-
anced, with 24% diabetic patients in the nifedipine-treated
group and 13% in the other group. The Blood Pressure
Trialists (7) omitted both CASTEL and the Fosinopril
versus Amlodipine Cardiovascular Events Trial (FACET)
(15) from their prospective meta-analysis.
The second part of the study compares initial CCB
therapy with ACE inhibitor therapy (Table 3). Here, there
was only one satisfactory study—STOP-Hypertension-2
(4). The STOP-Hypertension-2 diabetic substudy of 719
patients was classified as grade A, lacking only the sample
size criterion (20). Appropriate Blood pressure Control in
Diabetes (ABCD) is a difficult trial to assess, because it was
terminated prematurely, and especially because the out-
comes in the final report differed substantially from those
already published (14). Therefore, although it was random-
ized and double-blinded, ABCD was assigned to grade B.
The FACET was graded as B; it was open-labeled, the
primary and secondary end points were not clearly defined,
some data were lacking and the clinical events were analyzed
retrospectively.
A joint analysis of grade A trials is presented. Further-
more, to assess the sensitivity of the results to the entry
criteria for the meta-analysis, a joint analysis of grade A and
B trials is also presented. To further assess the sensitivity,
there is also an analysis excluding MIDAS, which has the
lowest number of points in grade B (Table 1). Combined
estimates of relative risk (RR), with 95% confidence inter-
vals (CIs), across studies were calculated by the Mantel-
Haenszel method, with “trial” as the stratification factor.
Combined p values were obtained by the Cochran-Mantel-
Haenszel chi-square test, but p values for individual studies
were obtained from the Fisher exact test. The homogeneity
of the odds ratio across trials was tested using the Breslow-
Day test. The Bonferroni correction was used to assess the
possible effect of multiple comparisons (21). We reasoned
that the four primary events in the trials were nonfatal and
fatal stroke and nonfatal and fatal MI, with other events
Abbreviations and Acronyms
ABCD  Appropriate Blood pressure
Control in Diabetes trial
ACE  angiotensin-converting enzyme
CASTEL  Cardiovascular Study of the
Elderly
CCB  calcium channel blocker
CI  confidence interval
FACET  Fosinopril versus Amlodipine
Cardiovascular Events Trial
MI  myocardial infarction
MIDAS  Multicenter Isradipine Diuretic
Atherosclerosis Study
RR  relative risk
STOP-Hypertension  Swedish Trial in Old Patients
with Hypertension
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Table 1. Entry Criteria as Met by Trials Comparing Calcium Channel Blockers With Conventional Therapy
Criterion
INSIGHT
(Ref. 3)
STOP-
Hypertension-2
(Ref. 4)
NORDIL
(Ref. 5)
NICS-EH
(Ref. 11)
VHAS
(Ref. 12)
MIDAS
(Ref. 13)
Randomized 1 1 1 1 1 1
CCB vs. diuretic CCB vs. diuretic or
beta-blocker
CCB vs. diuretic or beta-
blocker
CCB vs. diuretic CCB vs. diuretic CCB vs. diuretic
Double-blinded or PROBE
design*
1 1 1 1 0 1
Double-blinded PROBE PROBE Double-blinded Double-blinded; then
open-label
Double-blinded; 3 years
Predefined clinical end points;
primary end points
1 1 1 0 0 0
Total CV morbidity Fatal CV disease Stroke, MI, all CV deaths CV events Not given Not given
Not short-acting CCB;
specific drug used
1 1 0 1 1 0
nifedipine GITS felodipine or
isradipine
diltiazem, initially short-
acting
nicardipine verapamil, slow release isradipine, short-acting
Large trial (1,000) 1 1 1 0 1 0
Total number 6,321 6,614 10,881 414 1,414
Duration 2 years 1 1 1 1 1 1
(at least 3 years) (up to 6 years) (up to 5 years) 5 years 2 years
Total points 6 6 5 4 4 3
*PROBE  Prospective, Randomized, Open, Blinded Endpoint evaluation design; see test for details.
CCB  calcium channel blocker; CV  cardiovascular; GITS  gastro-intestinal tract system; MI  myocardial infarction; trial acronyms are defined in the references.
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such as heart failure and mortality not independent of these
four.
RESULTS
Comparisons of CCBs with conventional therapy. In
grade A studies with 21,611 subjects, total mortality (RR
1.005, CI 0.914 to 1.105) and cardiovascular mortality were
indistinguishable for the two modes of therapy (CCBs vs.
conventional therapy), as was the risk of major cardiovas-
cular events (Tables 2 and 3, Fig. 1). The risk of nonfatal
stroke for CCBs compared with conventional therapy was
25% lower (p 0.001), and the risk of MI, chiefly nonfatal,
was 19% higher (p  0.011). The risk of heart failure was
indistinguishable, although there was a trend against the
CCBs. Adding in the grade B studies yielded a total of
24,322 subjects, again with indistinguishable total and
cardiovascular mortality, a lower risk of nonfatal stroke
(25%, p 0.001) and a higher risk of MI (18%, p 0.013),
chiefly nonfatal (18%, p  0.036) for CCBs compared with
conventional therapy. Note that all of these p values are not
necessarily significant, albeit p  0.05. When using the
Bonferroni correction for the four basic events covered in
our analyses, these p values increased to 0.004, 0.044, 0.004,
0.052 and 0.144, respectively. Thus, the most statistically
robust finding was related to a reduction of nonfatal stoke by
CCBs. The overall findings are unchanged by omitting
MIDAS (13), the weakest of the grade B studies.
Comparisons of CCBs with ACE inhibitors. There was
only one grade A study—STOP-Hypertension-2 (4). This
study showed differences favoring ACE inhibition that
become insignificant with the Bonferroni correction. Com-
bining three studies with a total of 1,318 diabetic hyperten-
sive patients—namely, the STOP-Hypertension-2 diabetic
study with the corrected ABCD data (used herein) and the
small, open-label, data-deficient FACET (15)—
accentuated the differences in favor of ACE inhibition
(Table 4, Fig. 2). Thus, in diabetics, CCBs are related to a
substantially higher risk of nonfatal (RR 2.259) and total
MI (RR 2.204, CI 1.501 to 3.238; p  0.001 or 0.004 with
Bonferroni correction). Nonetheless, CCBs and ACE in-
hibitors have similar rates of total and cardiovascular mor-
tality. This can be explained by the increased the risk of
nonfatal, but not fatal, MI with the use of CCBs.
Homogeneity of data across studies. P values for the
Breslow-Day test were 0.05. For the major events (total
and cardiovascular mortality and major cardiovascular
events), p  0.49, except in the smaller diabetic trials.
DISCUSSION
Our major conclusion is that, over the periods of study,
CCBs appear to be safe and effective when compared with
conventional therapy, defined as initiation of therapy with
either a diuretic or beta-blocker. The risks of total and
cardiovascular mortality, as well as major cardiovascular
Table 2. Stroke: Calcium Channel Blocker-Based Therapy Versus Conventional Therapy
of Hypertension
CCB (n/N) CT (n/N) RR* 95% CI p Value Heterogeneity†
Stroke, nonfatal
INSIGHT (ref. 3) 55/3,157 63/3,164 0.875 0.611–1.252 0.516
NORDIL (ref. 5) 138/5,410 174/5,471 0.802 0.644–1.000 0.051
STOP-2 (ref. 4) 120/2,196 186/2,213 0.650 0.521–0.812 0.001
Total, grade A 313/10,763 423/10,848 0.746 0.647–0.860 0.001 0.227
VHAS (ref. 12) 3/707 4/707 0.750 0.168–3.339 1.000
NICS-EH (ref. 11) 8/204 8/210 1.029 0.394–2.691 1.000
MIDAS (ref. 13) No data No data No data No data No data
Total of above 324/11,674 435/11,765 0.751 0.653––0.864 0.001 0.495
Stroke, fatal
INSIGHT 12/3,157 11/3,164 1.093 0.483–2.474 0.838
NORDIL 21/5,410 22/5,471 0.965 0.531–1.753 1.000
STOP-2 207/2,196 237/2,213 0.880 0.737–1.050 0.161
Total, grade A 240/10,763 270/10,848 0.896 0.759–1.058 0.194 0.829
VHAS 3/707 0/707 ‡ ‡ 0.249
NICS-EH 3/204 0/210 ‡ ‡ 0.119
MIDAS No data No data No data No data No data
Total of above 246/11,674 270/11,765 0.918 0.779–1.083 0.311 0.127
Total stroke
INSIGHT 67/3,157 74/3,164 0.907 0.654–1.258 0.610
NORDIL 159/5,410 196/5,471 0.820 0.668–1.008 0.059
STOP-2 207/2,196 237/2,213 0.880 0.737–1.050 0.161
Total, grade A 433/10,763 507/10,848 0.861 0.761–0.975 0.018 0.849
VHAS 3/707 4/707 0.750 0.168–3.339 1.000
NICS-EH 8/204 8/210 1.029 0.394–2.691 1.000
Total grades A and B 450/12,116 522/12,206 0.869 0.769–0.982 0.024 0.849
*RR relative risk of calcium channel blocker (CCB) therapy versus conventional therapy (CT); CI confidence interval. †The
Breslow-Day test was used for heterogeneity; ‡Statistics were not calculated for empty cells.
Trial acronyms are defined in the references.
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outcomes, were apparently indistinguishable when compar-
ing CCBs and conventional therapy (Tables 2 and 3).
Conventional therapy, as compared with placebo, is known
to reduce mortality in elderly hypertensive patients (22).
Two placebo-controlled trials of CCB-based therapy also
showed reduced total mortality (23,24). Therefore, it is
reasonable to deduce that CCB-based therapy, as compared
with placebo, for hypertension potentially reduces all-cause
mortality, depending on the patient’s risk profile.
Quality of the meta-analysis. The quality of any meta-
analysis, including ours, partly depends on the combinability
of the information provided by the trials, the quality of the
trial designs and the carefulness of the clinical data collec-
tion. These requirements were not all satisfactorily met in
the various studies, which led us to use a grading system in
the present meta-analysis. Of note, even the grade A studies
differ with respect to clinical factors such as patient age and
final blood pressure achieved. The mortality rate in STOP-
Hypertension-2 (4) was 16.7%, but 5% in the other two
grade A trials (3,5). However, although the absolute risk
levels vary considerably across studies, the RRs for total and
cardiovascular mortality, major cardiovascular events,
stroke, nonfatal MI and all MIs are homogeneous across the
studies (see the p values for Breslow-Day test). This justifies
combining the estimates of RR across the studies and
Table 3. Myocardial Infarction, Heart Failure and Major Cardiovascular Events: Calcium
Channel Blocker-Based Therapy Versus Conventional Therapy of Hypertension
CCB (n/N) CT (n/N) RR* 95% CI p Value Heterogeneity†
MI, nonfatal
INSIGHT (ref. 3) 61/3,157 56/3,164 1.092 0.762–1.564 0.642
NORDIL (ref. 5) 155/5,410 132/5,471 1.187 0.944–1.493 0.151
STOP-2 (ref. 4) 120/2,196 99/2,213 1.222 0.942–1.583 0.145
Total grade A 336/10,763 287/10,848 1.180 1.011–1.378 0.036 (0.872)
VHAS (ref. 12) 5/707 5/707 1.000 0.291–3.439 1.000
NICS-EH (ref. 11) 2/204 2/210 1.029 0.146–7.239 1.000
MIDAS (ref. 13) 6/442 5/441 1.197 0.368–3.894 1.000
Total grades A and B 349/12,116 299/12,206 1.177 1.011–1.370 0.036 (0.996)
MI, fatal
INSIGHT 16/3,157 5/3164 3.207 1.176–8.744 0.017
NORDIL 28/5,410 25/5471 1.133 0.661–1.940 0.681
STOP-2 59/2,196 55/2213 1.081 0.752–1.553 0.705
Total grade A 103/10,763 85/10848 1.222 0.919–1.623 0.168 (0.115)
VHAS 3/707 4/707 0.750 0.168–3.339 1.000
NICS-EH 0/204 0/210 — — ‡
MIDAS — — — — ‡
Total grades A and B 106/11,674 89/11,765 1.200 0.908–1.587 0.200 (0.193)
MI, total
INSIGHT 77/3,157 61/3,164 1.265 0.907–1.764 0.169
NORDIL 183/5,410 157/5,471 1.179 0.956–1.454 0.137
STOP-2 179/2,196 154/2,213 1.171 0.952–1.441 0.139
Total grade A 439/10,763 372/10,848 1.190 1.040–1.361 0.011 (0.935)
VHAS 8/707 9/707 0.889 0.345–2.291 1.000
NICS-EH 2/204 2/210 1.029 0.146–7.239 1.000
MIDAS 6/442 5/441 1.197 0.368–3.894 1.000
Total grades A and B 455/12,116 388/12,206 1.182 1.036–1.349 0.013 (0.991)
Heart failure
Total grades A and B 279/12,116 245/12,206 1.148 0.972–1.356 0.104 (0.054)
Major CV events
Total grades A and B 1,261/12,116 1257/12,206 1.011 0.940–1.087 0.767 (0.749)
Total CV mortality
Total grades A and B 411/12,116 395/12,206 1.049 0.917–1.199 0.486 (0.805)
*RR relative risk of calcium channel blocker (CCB) therapy versus conventional therapy (CT); CI confidence interval. †The
Breslow-Day test was used for heterogeneity; ‡Statistics were not calculated for empty cells.
(—)  absence of data; CV  cardiovascular; MI  myocardial infarction; trial acronyms are defined in the references.
Figure 1. Comparison between calcium channel blocker (CCB) based
therapy and conventional therapy. For details, see Tables 2 and 3. Note the
decrease (p  0.001) in nonfatal stroke and the increase in nonfatal
myocardial infarction (MI) (p  0.036). CV  cardiovascular.
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suggests that the relative efficacy and safety of CCBs may
withstand the differences in clinical factors between the
trials included in this analysis. Furthermore, by using our
grading system, we could show that inclusion of grade B
trials in the meta-analysis, a procedure that constitutes a
limited sensitivity analysis, did not materially affect the
results. This suggests a certain robustness of our findings in
relation to the inclusion criteria for the trials in this
meta-analysis. Of note, neither the other investigators nor
we (6,7) used funnel plots in the meta-analyses presented,
because of the relatively small number of trials.
All meta-analyses may suffer from inclusion and exclusion
bias (25) and from the inherent statistical weakness of the
data included. We have attempted to avoid bias by analyzing
all of the trials cited by Furberg’s group (6) and by using our
grading system, as well as by giving full reasons for rejection
of one study. Meta-analyses, which by nature involve
multiple comparisons, may require a very low p value,
possibly as low as 0.001, to reach significance with confi-
dence (26). This value was reached for the CCB effect on
nonfatal stroke (Table 2). We also provide Bonferroni
corrections in an attempt to compensate for the inevitable
multiple comparisons made in our analyses. In addition,
each trial had multiple outcomes. For these reasons, rela-
tively small differences between CCB and conventional
therapy should be regarded with reserve, whereas the lack of
Figure 2. Comparison between calcium channel blocker (CCB) based
therapy and angiotensin-converting enzyme (ACE) inhibitor-based ther-
apy. For details, see Table 4. Note the increase in nonfatal and total
myocardial infarction (MI). CV  cardiovascular.
Table 4. Diabetic Hypertensive Therapy Based on Calcium Channel Blockers and Angiotensin-
Converting Enzyme Inhibitors
CCB
(n/N)
ACE Inhibitors
(n/N) RR* 95% CI
p
Value Heterogeneity†
Stroke
STOP-2, nondiabetic (ref. 4) 178/1,965 181/1,968 0.985 0.809–1.200 0.912
STOP-2, diabetic, grade A
(ref. 20)
29/231 34/237 0.875 0.552–1.388 0.591
ABCD, diabetic, grade B
(ref. 14)
11/235 7/235 1.571 0.620–3.984 0.472
FACET, diabetic, grade B
(ref. 15)
10/191 4/189 2.474 0.790–7.750 0.172
Total diabetic 50/657 45/661 1.129 0.770–1.654 0.535 (0.176)
MI, nonfatal
STOP-2, nondiabetic 52/1,965 44/1,968 1.184 0.796–1.760 0.411
STOP-2, diabetic, grade A 25/231 13/237 1.973 1.035–3.761 0.042
ABCD, diabetic, grade B 24/235 9/235 2.667 1.267–5.614 0.010
Total diabetic 49/466 22/472 2.259 1.410–3.618 0.001 (0.561)
MI, fatal
STOP-2, nondiabetic 52/1,965 44/1,968 1.184 0.796–1.760 0.411
STOP-2, diabetic, grade A 7/231 4/237 1.795 0.533–6.051 0.377
ABCD, diabetic, grade B 3/235 0/235 — ‡ 0.248
Total diabetic 10/466 4/472 2.555 0.842–7.755 0.098 (0.223)
MI, all
STOP-2, nondiabetic 147/1,965 122/1,968 1.207 0.957–1.522 0.115
ABCD, diabetic, grade B 27/235 9/235 3.000 1.442–6.240 0.001
FACET, diabetic, grade B 13/191 7/189 1.838 0.750–4.505 0.250
STOP-2, diabetic, grade A 32/231 17/237 1.931 1.104–3.380 0.023
Total diabetic 72/657 33/661 2.204 1.501–3.238 0.001 (0.597)
Heart failure
STOP-2, nondiabetic 162/1,965 127/1,968 1.278 1.021–1.598 0.032
STOP-2, diabetic, grade A 24/231 22/237 1.119 0.646–1.939 0.757
ABCD, diabetic, grade B 8/235 10/235 0.800 0.321–1.991 0.811
Total diabetic 32/466 32/472 1.019 0.637–1.630 0.939 (0.534)
Major CV events 115/466 93/472 1.258 0.992–1.595 0.059 (0.075)
*RR relative risk of calcium channel blocker (CCB) therapy versus conventional therapy (CT); CI confidence interval. †The
Breslow-Day test was used for heterogeneity; ‡Statistics were not calculated for empty cells.
(—)  absence of data; ACE  angiotensin-converting enzyme; CV  cardiovascular; MI  myocardial infarction; trial
acronyms are defined in the references.
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difference in relation to the major outcomes, such as
cardiovascular mortality and major events, is striking. How-
ever, we cannot exclude that with larger numbers, some of
the trends, such as those in heart failure, might show
adverse effects for CCBs, in keeping with the CIs (Fig. 1),
which, in turn, would influence major cardiovascular events.
Hypertension in diabetics. When compared with ACE
inhibitors in diabetic hypertensive patients, CCBs have an
apparently indistinguishable effect on total and cardiovas-
cular mortality, stroke and heart failure (Table 4). However,
CCBs have a substantially higher risk of nonfatal (RR
2.259) and total MI (RR 2.204, CI 1.501 to 3.238; p 
0.001 or 0.004 with Bonferroni correction). In nondiabetics,
these changes did not reach significance. However, these
conclusions must still be viewed with caution. Subgroup
analysis, even with multiplicity correction, is only justi-
fied if the overall trial shows little benefit (as for mortality
in this meta-analysis) and if the hypothesis regarding
subgroup effects has a strong biologic rationale (26). We
tested the hypothesis that ACE inhibitors are superior to
CCBs in hypertensive diabetic patients. However, STOP-
Hypertension-2 is the only grade A study based on the
comparison of CCBs and ACE inhibitors (4). Furthermore,
the total number of diabetic hypertensive patients (n 
1,318) and trials (n  3) comparing CCBs and ACE
inhibitors is much less than that in comparisons between
CCBs and conventional therapy (n  24,322 and 6 trials),
giving much greater credence to the conclusions derived
from the latter comparison. Regarding diabetic nephropa-
thy, a recent study (27) shows that inhibition of the
renin-angiotensin system by irbesartan is superior to amlo-
dipine in renal end point reduction, yet amlodipine reduced
MI by 41%.
Our data help to interpret the apparently conflicting
conclusions of the two previous meta-analyses. Furberg’s
group did not mention in their abstract or discussion that
comparing CCBs with conventional therapy gave a small
reduction in stroke (14%) and a small increase in heart
failure (20%) and MI (22%), with p values (0.05) that
would lose significance when Bonferroni-corrected (6). In
contrast, when comparing CCBs with ACE inhibitors, MI
was increased (43%), with a very low p value (p  0.001).
We suggest that it is the inclusion of the ACE inhibitor
data, together with data on conventional therapy, that skews
the overall Furberg meta-analysis toward inferiority of the
CCBs. Like us, the Blood Pressure Trialists separated the
comparison of CCBs with conventional therapy from that
with ACE inhibitors and found virtual equality with con-
ventional therapy. The Blood Pressure Trialists could find
no clear evidence of differences between ACE inhibitors and
CCBs (7), even though ACE inhibitors appear to have
strong protective effects, when compared with placebo, in
high-risk diabetic patients (10). However, they did not have
data on the diabetic subgroup of STOP-Hypertension-2.
These are the data that, together with the lower grade B
studies previously available (i.e., ABCD and FACET),
argue for the inferiority of CCBs versus ACE inhibition in
diabetic patients. Of note, Furberg’s group included two
diabetic studies and the Blood Pressure Trialists included only
one, whereas we separately considered three diabetic studies.
Yet the diabetic database remains small. Additional data from
currently running, well-designed trials, such as the Antihyper-
tensive and Lipid Lowering treatment to prevent Heart Attack
Trial, are required to confirm the superiority of ACE inhibitors
in hypertensive diabetic patients.
Study limitations. There are several limitations of our
study. First, we collected data retrospectively. Likewise, this
is a defect of the Furberg study (6), although not of the
Blood Pressure Trialists’ study, which was prospective (7). A
second defect of our study, and of both the others, is the
substantial number of statistical tests undertaken, with
many subgroups, to give the primary data. The limits of
statistical significance are difficult to define with precision.
However, we did use the Bonferroni correction, which
neither of the other studies did, despite their analyses of
numerous subgroups. We have shown that several of the
differences noted in the other two studies (6,7) became
insignificant when thus corrected. Third, none of the studies
relate the comparisons between CCBs and ACE inhibitors
to renal outcomes in hypertensive patients. In the African
American Study of Kidney Disease and Hypertension of
African Americans with hypertensive renal disease, the
amlodipine arm was withdrawn because of worse renal
outcomes at equal blood pressure reductions, whereas the
ramipril arm continued (28). Thus, in situations where there
is a high risk of renal involvement (e.g., diabetics, African
Americans), there is emerging evidence that dihydropyri-
dines are inferior to inhibition of the renin-angiotensin
system. Fourth, and most importantly, controlled trials are
time-limited by their nature, whereas antihypertensive ther-
apy is often life-long. Very long-term data may yet emerge
from carefully designed, prospective, observational data.
Conclusions. We propose that CCBs are safe in the
therapy of hypertension over the periods tested, with risks of
mortality (total and cardiovascular) and major cardiovascular
events apparently similar to those of conventional first-line
therapy with diuretics or beta-blockers. However, in dia-
betic hypertensive patients, ACE inhibition may give supe-
rior cardiovascular protection, specifically against nonfatal
MI. This proposal, although based on a statistically robust
difference, is only provisional, because of the limited data-
base. Further comparative data are required.
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